Free Trial
NASDAQ:IPHA

Innate Pharma (IPHA) Stock Price, News & Analysis

Innate Pharma logo
$2.17 +0.06 (+2.84%)
As of 08/1/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Innate Pharma Stock (NASDAQ:IPHA)

Key Stats

Today's Range
$2.14
$2.22
50-Day Range
$1.70
$2.20
52-Week Range
$1.29
$3.51
Volume
10,387 shs
Average Volume
13,151 shs
Market Capitalization
$198.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Buy

Company Overview

Innate Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

IPHA MarketRank™: 

Innate Pharma scored higher than 47% of companies evaluated by MarketBeat, and ranked 562nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Innate Pharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Innate Pharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Innate Pharma's stock forecast and price target.
  • Percentage of Shares Shorted

    0.06% of the outstanding shares of Innate Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Innate Pharma has recently decreased by 14.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Innate Pharma does not currently pay a dividend.

  • Dividend Growth

    Innate Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.06% of the outstanding shares of Innate Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Innate Pharma has recently decreased by 14.33%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Innate Pharma this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Innate Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.16% of the stock of Innate Pharma is held by institutions.

  • Read more about Innate Pharma's insider trading history.
Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

IPHA Stock News Headlines

IPHA Innate Pharma S.A. - Seeking Alpha
Microsoft's Next Big Bet?
Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-free energy. Bill Gates calls it “abundant” and is backing four separate startups in the space. While most of these plays are off-limits to everyday investors, a little-known backdoor could give you access to one tiny company leading the charge—and it’s publicly traded.
See More Headlines

IPHA Stock Analysis - Frequently Asked Questions

Innate Pharma's stock was trading at $1.84 on January 1st, 2025. Since then, IPHA stock has increased by 16.8% and is now trading at $2.15.

Innate Pharma (IPHA) raised $80 million in an initial public offering (IPO) on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI acted as the underwriters for the IPO.

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Pfizer (PFE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Altimmune (ALT), Cidara Therapeutics (CDTX) and Fulcrum Therapeutics (FULC).

Company Calendar

Today
8/01/2025
Next Earnings (Estimated)
9/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IPHA
CIK
1598599
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$11.00
Potential Upside/Downside
+411.6%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
2.52
Current Ratio
2.60
Quick Ratio
2.60

Sales & Book Value

Annual Sales
$12.62 million
Price / Sales
15.70
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.11 per share
Price / Book
19.55

Miscellaneous

Outstanding Shares
92,184,000
Free Float
62,787,000
Market Cap
$198.20 million
Optionable
Not Optionable
Beta
0.21

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:IPHA) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners